Chapter 1: Masters Thesis Literature Review
... animal models used for studying M. tuberculosis infection are; the mouse, rabbit, guinea pig and non-human primate [17]. While none are perfect models, they each have their advantages and disadvantages. The murine model is by far the most commonly used within research and during early drug testing. ...
... animal models used for studying M. tuberculosis infection are; the mouse, rabbit, guinea pig and non-human primate [17]. While none are perfect models, they each have their advantages and disadvantages. The murine model is by far the most commonly used within research and during early drug testing. ...
Antibody Repertoire and Gene Expression Profile
... (MZ)4 B cells enriched in the MZ surrounding the splenic lymphoid follicles, and B-1 lymphocytes, which can be subdivided into B-1a cells expressing CD5 and the CD5⫺ B-1b sister population (1, 2). Physiologically, B-1a cells are more dependent on signals via the B cell receptor (BCR) than are B-2 ce ...
... (MZ)4 B cells enriched in the MZ surrounding the splenic lymphoid follicles, and B-1 lymphocytes, which can be subdivided into B-1a cells expressing CD5 and the CD5⫺ B-1b sister population (1, 2). Physiologically, B-1a cells are more dependent on signals via the B cell receptor (BCR) than are B-2 ce ...
Mainstream- Fringe- and Patho- Physiology of Voltage Dependent
... conduction in excitable tissue in a range of experimental procedures. Local anesthetics and related compounds, such as QX-222 and QX-314, block Nav channels by binding to an intracellular site near the pore. These agents are capable of blocking all Nav isoforms when applied intracellularly. However, ...
... conduction in excitable tissue in a range of experimental procedures. Local anesthetics and related compounds, such as QX-222 and QX-314, block Nav channels by binding to an intracellular site near the pore. These agents are capable of blocking all Nav isoforms when applied intracellularly. However, ...
Discovery of a highly potent, selective reversible covalent inhibitor of
... an IC50 of 0.5 ± 0.3 nM, but not JAK1, JAK2, or TYK2 up to a concentration of 5 uM. The selectivity among other kinases within the Cys sub-family was also high with no inhibition exceeding 60% at 1 uM. Profiling against a panel of 442 kinases confirmed the exceptional selectivity of the series. Comp ...
... an IC50 of 0.5 ± 0.3 nM, but not JAK1, JAK2, or TYK2 up to a concentration of 5 uM. The selectivity among other kinases within the Cys sub-family was also high with no inhibition exceeding 60% at 1 uM. Profiling against a panel of 442 kinases confirmed the exceptional selectivity of the series. Comp ...
Specific Control of Immunity by Regulatory CD8 T Cells
... host disease (GVHR) by induction of an anti-idiotypic response (38). For example, immunization of F1 rats with alloreactive T cell populations of parental strain origin induced a host-mediated T cell response that was specific for the anti-MHC receptors on the alloreactive parental T cells. The cell ...
... host disease (GVHR) by induction of an anti-idiotypic response (38). For example, immunization of F1 rats with alloreactive T cell populations of parental strain origin induced a host-mediated T cell response that was specific for the anti-MHC receptors on the alloreactive parental T cells. The cell ...
Localization of Receptors for Vasoactive Intestinal
... lymphocytes.13 VIP regulates immunocompetence in vitro including antibody production, natural killer activity, histamine production by mast cells, and lymphocyte proliferation.2,3 Effects of SP on immunocompetence have also been documented19 and are probably exerted through the carboxyterminal domai ...
... lymphocytes.13 VIP regulates immunocompetence in vitro including antibody production, natural killer activity, histamine production by mast cells, and lymphocyte proliferation.2,3 Effects of SP on immunocompetence have also been documented19 and are probably exerted through the carboxyterminal domai ...
High salivary secretory IgA antibody levels are sensitized infants
... well as absorption of foreign substances (6). Plasma cells in the mucosal lamina propria secrete dimeric IgA associated with a single J chain (6). This form of IgA binds to the polymeric Ig receptor (pIgR) on the basolateral surfaces of the overlying epithelial cells. The bound complex then undergoe ...
... well as absorption of foreign substances (6). Plasma cells in the mucosal lamina propria secrete dimeric IgA associated with a single J chain (6). This form of IgA binds to the polymeric Ig receptor (pIgR) on the basolateral surfaces of the overlying epithelial cells. The bound complex then undergoe ...
Nio-Kobayashi et al revised version
... alterations in the tubal environment that results in early implantation [Shaw et al., 2010b]. ...
... alterations in the tubal environment that results in early implantation [Shaw et al., 2010b]. ...
Chapter 1: Induction Therapy
... There have been few head-to-head comparisons of different lymphocyte-depleting agents. Thus, it is unclear whether any one of these agents is superior to any other. In meta-analyses, there do not appear to be obvious differences in the effects of different lymphocyte-depleting agents on acute reject ...
... There have been few head-to-head comparisons of different lymphocyte-depleting agents. Thus, it is unclear whether any one of these agents is superior to any other. In meta-analyses, there do not appear to be obvious differences in the effects of different lymphocyte-depleting agents on acute reject ...
HEVs, lymphatics and homeostatic immune cell trafficking in lymph
... bulk of lymphocyte trafficking to lymph nodes. During homeostasis, HEVs are found only in lymphoid organs, but they can develop in non-lymphoid tissues during chronic inflammatory diseases6,24 and cancer 25, and they are associated with high levels of lymphocyte infiltration into these tissues (BOX ...
... bulk of lymphocyte trafficking to lymph nodes. During homeostasis, HEVs are found only in lymphoid organs, but they can develop in non-lymphoid tissues during chronic inflammatory diseases6,24 and cancer 25, and they are associated with high levels of lymphocyte infiltration into these tissues (BOX ...
Chapter 13
... the MHC environment in which the T cells are selected, and not on the MHC genotype of the T cells themselves. This suggests that I-J is a V region shape or set of closely related shapes, which are selected due to the presence of MHC class II antigens. Most simply, I-J could then be either anti-MHC c ...
... the MHC environment in which the T cells are selected, and not on the MHC genotype of the T cells themselves. This suggests that I-J is a V region shape or set of closely related shapes, which are selected due to the presence of MHC class II antigens. Most simply, I-J could then be either anti-MHC c ...
Characterization of amoxicillin‐and clavulanic acid‐specific T cells
... Drug-induced liver injury (DILI) frequently has a delayed onset with several human leukocyte antigen (HLA) genotypes affecting susceptibility, indicating a potential role for the adaptive immune system in the disease. The aim of this study was to investigate whether drug-responsive T lymphocytes are ...
... Drug-induced liver injury (DILI) frequently has a delayed onset with several human leukocyte antigen (HLA) genotypes affecting susceptibility, indicating a potential role for the adaptive immune system in the disease. The aim of this study was to investigate whether drug-responsive T lymphocytes are ...
Mechanisms of Salivary Gland Secretory Dysfunction in Sjögren`s
... Recently, not only TH1 and TH2 effector cells but also TH17 cells, which mainly release proinflammatory cytokine IL-17, are being investigated for their role in disease pathogenesis of many autoimmune diseases including SS. The presence of TH17 cells and TH17-associated cytokines, IL-6, IL-23, IL-17 ...
... Recently, not only TH1 and TH2 effector cells but also TH17 cells, which mainly release proinflammatory cytokine IL-17, are being investigated for their role in disease pathogenesis of many autoimmune diseases including SS. The presence of TH17 cells and TH17-associated cytokines, IL-6, IL-23, IL-17 ...
Eradication and Cure of HIV - School of Biomedical Sciences
... to enhance CD8+ cytotoxic T cell activity ...
... to enhance CD8+ cytotoxic T cell activity ...
Autoimmune Diseases - The Dartmouth Undergraduate Journal of
... effect and scope of localized autoimmune disorders frequently extend beyond the initially targeted areas (6). The onset of autoimmune disease is associated with a trigger, which can be pulled in numerous ways. In one possible example, certain substance in the body that is normally confined to a spec ...
... effect and scope of localized autoimmune disorders frequently extend beyond the initially targeted areas (6). The onset of autoimmune disease is associated with a trigger, which can be pulled in numerous ways. In one possible example, certain substance in the body that is normally confined to a spec ...
BIOGRAPHICAL SKETCH Santambrogio, Laura
... Principal Investigator: Laura Santambrogio Agency: Italian Multiple Sclerosis Society Period: 01/01/1996 – 01/01/1999 “Role of Exosomes in HIV release from multivesicular bodies in CNS microglial cells” Principal Investigator: Laura Santambrogio Agency: NIH (CFAR Pilot Project) Period: 08/01/2004-12 ...
... Principal Investigator: Laura Santambrogio Agency: Italian Multiple Sclerosis Society Period: 01/01/1996 – 01/01/1999 “Role of Exosomes in HIV release from multivesicular bodies in CNS microglial cells” Principal Investigator: Laura Santambrogio Agency: NIH (CFAR Pilot Project) Period: 08/01/2004-12 ...
Activation of Innate Immune Responses by Non
... DC maturation and migration of the cells into local lymph nodes, where antigen presentation to naïve T cells and induction of adaptive immune responses takes place. During activation these cells produce cytokines, soluble mediators that regulate host immune responses. Recognition of microbes is regu ...
... DC maturation and migration of the cells into local lymph nodes, where antigen presentation to naïve T cells and induction of adaptive immune responses takes place. During activation these cells produce cytokines, soluble mediators that regulate host immune responses. Recognition of microbes is regu ...
2009/2010 Collaborative Research Update
... o provide a logical, consistent and transparent framework for submission, review and selection of research applications for funding. • T o support the very best Australian research into prostate cancer, and to ensure that allocation of PCFA grant funds is guided by a clear strategic focus and a ...
... o provide a logical, consistent and transparent framework for submission, review and selection of research applications for funding. • T o support the very best Australian research into prostate cancer, and to ensure that allocation of PCFA grant funds is guided by a clear strategic focus and a ...
Cancer immunotherapy
Cancer immunotherapy (immuno-oncology) is the use of the immune system to treat cancer. Immunotherapies fall into three main groups: cellular, antibody and cytokine. They exploit the fact that cancer cells often have subtly different molecules on their surface that can be detected by the immune system. These molecules, known as cancer antigens, are most commonly proteins, but also include molecules such as carbohydrates. Immunotherapy is used to provoke the immune system into attacking the tumor cells by using these antigens as targets.Antibody therapies are the most successful immunotherapy, treating a wide range of cancers. Antibodies are proteins produced by the immune system that bind to a target antigen on the cell surface. In normal physiology the immune system uses them to fight pathogens. Each antibody is specific to one or a few proteins. Those that bind to cancer antigens are used to treat cancer. Cell surface receptors are common targets for antibody therapies and include the CD20, CD274, and CD279. Once bound to a cancer antigen, antibodies can induce antibody-dependent cell-mediated cytotoxicity, activate the complement system, or prevent a receptor from interacting with its ligand, all of which can lead to cell death. Multiple antibodies are approved to treat cancer, including Alemtuzumab, Ipilimumab, Nivolumab, Ofatumumab, and Rituximab.Cellular therapies, also known as cancer vaccines, usually involve the removal of immune cells from the blood or from a tumor. Immune cells specific for the tumor are activated, cultured and returned to the patient where the immune cells attack the cancer. Cell types that can be used in this way are natural killer cells, lymphokine-activated killer cells, cytotoxic T cells and dendritic cells. The only cell-based therapy approved in the US is Dendreon's Provenge, for the treatment of prostate cancer.Interleukin-2 and interferon-α are examples of cytokines, proteins that regulate and coordinate the behaviour of the immune system. They have the ability to enhance anti-tumor activity and thus can be used as cancer treatments. Interferon-α is used in the treatment of hairy-cell leukaemia, AIDS-related Kaposi's sarcoma, follicular lymphoma, chronic myeloid leukaemia and malignant melanoma. Interleukin-2 is used in the treatment of malignant melanoma and renal cell carcinoma.